The Top 5 Biosimilars Articles for the Week of October 14, 2019
The Center for Biosimilars® recaps the top stories for the week of October 14, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 14, 2019.
Number 5: A pharmacists’ group has issued a global position statement in which it recommends against treating biosimilars as interchangeable.
Number 4: A new bill would amend the Affordable Care Act to allow insulins to be approved under abbreviated new drug applications as of 2020.
Number 3: The Congressional Budget Office and CMS report that the Lower Drug Costs Now Act would save on federal spending and improve health, at least in the short term.
Number 2: In a memorandum in support of its motion to dismiss an antitrust lawsuit, AbbVie said that the complaint could upend the balance between patent and antitrust laws and hurt innovation.
Number 1: Newly introduced bipartisan legislation would require HHS to evaluate Medicare Advantage plans based on whether biosimilars are available to enrollees.
Finally, last week, our e-newsletter asked whether you think that the UK Labour party’s proposal to use compulsory licensing in order to let the government develop cheaper generics is warranted.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
